



Search

About Cancer Cancer Types Research Grants & Training News & Events About NCI

Home Publications NCI Dictionaries NCI Drug Dictionary

- Publications
- Patient Education Publications

PDQ®

Fact Sheets

NCI Dictionaries

Dictionary of Cancer Terms

Drug Dictionary

Dictionary of Genetics Terms

Blog and Newsletters

Health Communications Publications

Reports

nivolumab

View Patient Information

A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.

Check for active clinical trials using this agent
View this agent in the NCI Thesaurus

Synonym:	nivolumab biosimilar ABP 206 nivolumab biosimilar BCD-263 nivolumab biosimilar CMAB819
US brand name:	Opdivo
Abbreviation:	NIVO
Code name:	ABP 206 BMS-936558 CMAB819 MDX-1106 ONO-4538

Search NCI's Drug Dictionary

☒ Starts with ☐ Contains

Search

Please enter up to 30 characters for your search

Browse: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z #

About
About This Website
en Español
Reuse & Copyright
Social Media

Resources
Contact Us
Publications
Dictionary of Cancer Terms
Find a Clinical Trial

Policies
Accessibility
FOIA
Privacy & Security
Disclaimers
Vulnerability Disclosure

Sign up for email updates

Enter your email address

Sign up

National Cancer Institute
at the National Institutes of Health

Follow us



Contact Us

Live Chat 1-800-4-CANCER NCInfo@nih.gov Site Feedback

U.S. Department of Health and Human Services
National Institutes of Health
National Cancer Institute
USA.gov